TCT 2026:28项最新临床研究将发布,引领介入心脏病学新进展
TCT 2026丨28项最新临床研究,引领全球介入心脏病学新进展
美国经导管心血管治疗学术会议(TCT 2026)将于2026年10月31日至11月3日在圣地亚哥召开,会上将发布28项最新临床研究。多个Late-Breaking专场分别与The Lancet、Circulation、NEJM、EHJ、JACC、JAMA等期刊合作。研究覆盖冠脉介入、结构性心脏病、三尖瓣与二尖瓣介入、TAVR、左心耳封堵、药物球囊、FFR、肾去神经术等方向,其中多数为随机对照试验。
2026年10月31日至11月3日,美国经导管心血管治疗学术会议(TCT 2026)将在美国圣地亚哥隆重召开。作为全球介入心脏病学领域最具影响力的会议之一,TCT 2026 汇聚来自全球的介入心脏病专家、外科医师、影像医师以及护理人员,在推动介入心脏病学发展与规范临床实践的过程中发挥着重要作用。本届TCT设置了多场 Late-Breaking Clinical Trials / Late-Breaking Clinical Science,分别与 The Lancet、Circulation、NEJM、EHJ、JACC、JAMA等顶级期刊合作,涉及冠脉介入、结构性心脏病、三尖瓣介入、二尖瓣介入、左心耳封堵、TAVR、药物球囊、FFR、肾去神经术等新技术、新器械、新理念。接下来,让我们一起来看看今年TCT有哪些值得关注的最新临床研究。
Late-Breaking Clinical Trials: Session I, in Collaboration with The Lancet
北京时间:11月2日 02:45-04:13
Coronary CT Angiography-Guided vs. IVUS-Guided PCI: The Randomized P4 Trial
冠状动脉CT血管造影引导 vs. 血管内超声引导的PCI:随机P4试验
讲者:Carlos Collet
Sirolimus Coated Balloons vs. Drug-eluting Stents in Native Coronary Vessels: The TRANSFORM II Randomized Trial
西罗莫司涂层球囊 vs. 药物洗脱支架用于原生冠状动脉:TRANSFORM II随机试验
讲者:Bernardo Cortese
A Randomized Trial of Higher vs. Lower Dose Heparin for PCI: The HD-PCI Trial
PCI中较高剂量 vs. 较低剂量肝素的随机试验:HD-PCI试验
讲者:Sanjit S. Jolly
Coronary Sinus Reducer for Refractory Angina in ANOCA: A Randomized Double-Blind Sham-Controlled Trial (REMEDY-PILOT)
冠状窦减容器用于ANOCA难治性心绞痛:随机双盲假手术对照试验(REMEDY-PILOT)
讲者:Kevin Cheng
Late-Breaking Clinical Science: Session I, in Collaboration with Circulation
北京时间:11月2日 06:15-07:45
Characteristics and Clinical Outcomes of Tricuspid Regurgitation in the Community: Insights from a Real-World Cohort of 180,977 Men and Women
社区中三尖瓣反流的特征与临床结局:来自180,977名男女真实世界队列的见解
讲者:Rebecca T. Hahn
Transcatheter Tricuspid Valve Replacement with the LuX-Valve Plus System vs. Medical Therapy for Severe TR: The Randomized TRAVEL III Trial
LuX-Valve Plus系统经导管三尖瓣置换 vs. 药物治疗重度TR:随机TRAVEL III试验
讲者:葛均波 教授
Transcatheter Tricuspid Valve Intervention in Heart Failure: Key Subgroup Results from the TRIC-I-HF-DZHK24 Trial
心力衰竭中的经导管三尖瓣介入:TRIC-I-HF-DZHK24试验关键亚组结果
讲者:Jörg Hausleiter
One-Year Outcomes with the Amulet 360 Device for Left Atrial Appendage Closure: The VERITAS Amulet 360 Study
Amulet 360装置用于左心耳封堵的1年结局:VERITAS Amulet 360研究
讲者:Dhanunjaya Lakkireddy
Economic Outcomes and Cost-Effectiveness of TAVR for Asymptomatic Severe Aortic Stenosis: Results from the EARLY TAVR Trial
TAVR用于无症状重度主动脉瓣狭窄的经济结局与成本效果:EARLY TAVR试验结果
讲者:Neel Butala
Late-Breaking Clinical Trials: Session II, in Collaboration with the New England Journal of Medicine
北京时间:11月3日 01:40-03:10
TAVR or Clinical Surveillance for Moderate Aortic Stenosis: Primary Results of the PROGRESS Randomized Trial
TAVR或临床监测用于中度主动脉瓣狭窄:PROGRESS随机试验主要结果
讲者:Philippe Genereux
Global Burden and Outcomes of Degenerative Mitral Valve Disease: A 30-Year Analysis of the Global Burden of Disease Study
退行性二尖瓣疾病的全球负担与结局:全球疾病负担研究的30年分析
讲者:Juan F. Granada
Transcatheter Tricuspid Valve Repair with the PASCAL System vs. Medical Therapy for Severe, Symptomatic Tricuspid Regurgitation: Clinical and Health Status Outcomes from the CLASP II TR Randomized Trial
PASCAL系统经导管三尖瓣修复 vs. 药物治疗重度症状性三尖瓣反流:CLASP II TR随机试验的临床与健康状况结局
讲者:Suzanne V. Arnold, Charles J. Davidson
Antithrombotic Monotherapy After Left Atrial Appendage Occlusion: Primary Results of the SIMPLAAFY Randomized Trial
左心耳封堵后抗血栓单药治疗:SIMPLAAFY随机试验主要结果
讲者:Saibal Kar
Late-Breaking Clinical Science: Session II, in Collaboration with the European Heart Journal
北京时间:11月3日 06:15-07:45
One-Year Outcomes of the PeriSorb Bioresorbable Vascular Scaffold vs. Drug-Coated Balloon for Superficial Femoral Artery Disease: A Multicenter Randomized Trial
PeriSorb生物可吸收支架 vs. 药物涂层球囊用于股浅动脉疾病的1年结局:多中心随机试验
讲者:Yuan Che
Three-Year Outcomes of Sirolimus vs. Paclitaxel-Coated Balloons for Femoropopliteal Artery Disease: The Randomized SIRONA Trial
西罗莫司 vs. 紫杉醇涂层球囊用于股腘动脉疾病的3年结局:随机SIRONA试验
讲者:Ulf Teichgräber
Impact of Non-Culprit Lesion Severity on the Utility of Functional Coronary Angiography in Patients with STEMI and Multivessel Disease: The AIR STEMI Randomized Trial
非罪犯病变严重程度对STEMI合并多支病变患者功能性冠状动脉造影效果的影响:AIR STEMI随机试验
讲者:Simone Biscaglia
Angiography-Derived FFR Versus vs. Wire-Based FFR to Guide Coronary Revascularization: The LIPSIA-STRATEGY Trial
造影衍生FFR vs. 基于导丝的FFR指导冠状动脉血运重建:LIPSIA-STRATEGY试验
讲者:Nicolas Majunke
Intracoronary Delivery of Nicorandil for Prevention of No-Reflow in Patients Undergoing Primary PCI for STEMI: A Multicenter Randomized Trial
冠状动脉内给予尼可地尔预防直接PCI的STEMI患者无复流:多中心随机试验
讲者:Takashi Muramatsu
Late-Breaking Clinical Trials: Session III, in Collaboration with the Journal of the American College of Cardiology
北京时间:11月4日 02:45-04:15
Angiography-Derived FFR vs. Usual Care for Lesion Selection and Optimization in All-Comers PCI: Final Results of the PIONEER IV Randomized Trial
造影衍生FFR vs. 常规护理用于所有PCI患者的病变选择与优化:PIONEER IV随机试验最终结果
讲者:Patrick W. Serruys
Platelet Function Testing to Guide P2Y12 Inhibitor De-Escalation After ACS: The EPIC17-VERONICA Randomized Trial
血小板功能检测指导ACS后P2Y12抑制剂降阶治疗:EPIC17-VERONICA随机试验
讲者:Iñigo Lozano
Safety and Effectiveness of Radiofrequency Renal Denervation in the United States: Primary Results of the SPYRAL AFFIRM Post-Approval Study
射频肾去神经术在美国的安全性与有效性:SPYRAL AFFIRM批准后研究主要结果
讲者:David E. Kandzari
Single vs. Double ProGlide Devices for Access Site Closure After Transfemoral TAVR: The SINGLE-CLOSURE Trial
单 vs. 双ProGlide装置用于经股TAVR后穿刺点闭合:SINGLE-CLOSURE试验
讲者:王建安 教授
Long-Term Survival after Coronary Revascularization for Unprotected Left Main Disease (the IRISMAIN Registry): A Prospective, Multicenter, Multinational Cohort Study
无保护左主干病变冠状动脉血运重建后的长期生存(IRISMAIN注册研究):前瞻性、多中心、多国队列研究
讲者:Duk-Woo Park
Late-Breaking Clinical Science: Session III, in Collaboration with the Journal of the American Medical Association
北京时间:11月4日 04:20-05:50
Percutaneous Transcatheter Mitral Valve Replacement in Patients with Symptomatic Mitral Regurgitation: 2-Year Outcomes from the ENCIRCLE Trial
经导管二尖瓣置换用于症状性二尖瓣反流患者:ENCIRCLE试验2年结局
讲者:John G. Webb
The ProtEmbo® Cerebral Protection System During TAVR: Final Results of the Randomized PROTEMBO IDE Trial
TAVR期间ProtEmbo®脑保护系统:随机PROTEMBO IDE试验最终结果
讲者:Susheel K. Kodali
Transcatheter Aortic Valve Replacement with the JenaValve Trilogy System for Aortic Regurgitation in Patients with a Left Ventricular Assist Device: The JENA-VAD Study
JenaValve Trilogy系统经导管主动脉瓣置换用于左心室辅助装置患者的主动脉瓣反流:JENA-VAD研究
讲者:Torsten P. Vahl
Routine Post-Dilation vs. Conventional Deployment for Balloon-Expandable TAVR: The Randomized DUOTAP Trial
球囊扩张式TAVR常规后扩张 vs. 传统释放:随机DUOTAP试验
讲者:Maximilian Autherith
Transcatheter vs. Surgical AVR for Symptomatic, Severe Aortic Regurgitation: One-Year Outcomes from a Multicenter Randomized Trial
经导管 vs. 外科主动脉瓣置换用于症状性重度主动脉瓣反流:多中心随机试验1年结局
讲者:YAOFU ZHENG
版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
来源:梅斯医学·临床资讯 · news.medsci.cn